London’s FTSE 100 experienced an uptick on Tuesday, buoyed by the performance of pharmaceutical stocks following AstraZeneca’s decision to acquire a $2 billion stake in Summit Therapeutics, aimed at furthering cancer research. The blue-chip FTSE 100 index rose 0.34% to 10,721.48 points by 0925, while the midcap FTSE 250 climbed 0.24%. Pharma sector opens new Read More
